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Background: We evaluated the drug interaction proﬁle of Red Ginseng (RG) with respect to the activities
of major cytochrome P450 (CYP) enzymes and the drug transporter P-glycoprotein (P-gp) in healthy
Korean volunteers.
Methods: This article describes an open-label, crossover study. CYP probe cocktail drugs, caffeine, los-
artan, dextromethorphan, omeprazole, midazolam, and fexofenadine were administered before and after
RG supplementation for 2 wk. Plasma samples were collected, and tolerability was assessed. Pharma-
cokinetic parameters were calculated, and 90% conﬁdence intervals (CIs) of the geometric mean ratios of
the parameters were determined from logarithmically transformed data using analysis of variance after
RG administration versus before RG administration.
Results: Fourteen healthy male participants were evaluated, none of whom were genetically deﬁned as
poor CYP2C9, 2C19, and CYP2D6 metabolizers based on genotyping. Before and after RG administration,
the geometric least-square mean metabolic ratio (90% CI) was 0.870 (0.805e0.940) for caffeine to par-
axanthine (CYP1A2), 0.871 (0.800e0.947) for losartan (CYP2C9) to EXP3174, 1.027 (0.938e1.123) for
omeprazole (CYP2C19) to 5-hydroxyomeprazole, 1.373 (0.864e2.180) for dextromethorphan to dextro-
rphan (CYP2D6), and 0.824 (0.658e1.032) for midazolam (CYP3A4) to 1-hydroxymidazolam. The geo-
metric mean ratio of the area under the curve of the last sampling time (AUClast) for fexofenadine (P-gp)
was 0.963 (0.845e1.098). Administration of concentrated RG for 2 wk weakly inhibited CYP2C9 and
CYP3A4 and weakly induced CYP2D6. However, no clinically signiﬁcant drug interactions were observed
between RG and CYP and P-gp probe substrates.
Conclusion: RG has no relevant potential to cause CYP enzyme- or P-gp-related interactions.
Clinical trial registration number (ClinicalTrials.gov): NCT02056743.
Copyright  2016, The Korean Society of Ginseng, Published by Elsevier. This is an open access article
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Ginseng (Panax ginseng Meyer), one of the most popular herbal
medicines, has been used for thousands of years in many eastern
countries. Ginsenoside, a saponin that is the main active ingredient
of ginseng, is reported to have a wide range of pharmacological
activities, including stress reduction and homeostasis maintenance,
immunomodulation, antifatigue actions, platelet aggregation inhi-
bition, and anticancer effects [1].l Medicine of Chonbuk National Un
Korea.
ht  2016, The Korean Society of G
d/4.0/).Red Ginseng (RG) is produced when fresh ginseng root is
steamed prior to oven drying. The steaming process causes chem-
ical transformations and produces speciﬁc ginsengmetabolites that
have distinctive pharmacological activities [2]. The bioavailability
of ginsenosides such as ginsenoside Rg3 and Rh2 in RG is higher
relative to those of fresh ginseng [3].
Over the past years, a variety of pharmacokinetic interactions
between ginseng and cytochrome P450 (CYP) enzymes have been
described. In a review of the in vitro effects of ginsenosides on CYPiversity-Biomedical Research Institute of Chonbuk National University Hospital, 20,
inseng, Published by Elsevier. This is an open access article under the CC BY-NC-ND
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results in an increase in CYP3A4 activity [4]. In a study using rat
hepatocytes, ginseng extracts did not increase the expression of the
rat hepatic CYP2B1, CYP3A23, or CYP1A2 genes [5]. However,
administration of 500 mg of ginseng (standardized to 5% ginseno-
sides) in healthy individuals for 4 wk increased CYP3A4 enzyme
activity by approximately 34% [6]. In addition, ginsenoside me-
tabolites have been reported to have the potential to inhibit P-
glycoprotein (P-gp) [7e9].
Many of these interaction studies have been performed using
fresh ginseng. However, as RG contains a large amount of ginse-
noside metabolites (e.g., compound K, Rh2), which are reported to
inhibit the enzyme activities of CYP2A6, CYP2C9 and CYP3A4 [10],
RG products, when taken as supplements, may affect the activity of
CYP enzymes. Additionally, no studies to date have assessed the
inﬂuence of RG on the activity of P-gp in humans.
The present study was conducted to characterize the inﬂuence
of RG on the activity of CYP enzymes and P-gp through drug
interaction by using probe drugs, caffeine, losartan, dextrome-
thorphan, omeprazole, midazolam, and fexofenadine in healthy
human volunteers.
2. Methods
This study was approved by the Ministry of Food and Drug
Safety and the Institutional Review Board of Chonbuk National
University Hospital (Jeonju, Republic of Korea, IRB No.: CUH 2013-
04-002), and was conducted according to the Declaration of Hel-
sinki for biomedical research involving human participants and the
Guidelines for Good Clinical Practice. A detailed explanation of the
study was provided, and written informed consent was obtained
from all participants prior to screening.
2.1. Participants
Healthy volunteers aged 20e55 yr were enrolled. Each in-
dividual’s health was conﬁrmed by physical examinations, mea-
surements of vital signs, 12-lead electrocardiography (ECG),Fig. 1. Study design for evaluating the drug interaction of Red Ginseng with respect to the act
P-glycoprotein.serology (hepatitis B virus surface antigen, hepatitis B virus surface
antibody, hepatitis C virus antibody, and anti-HIV antibody), and
routine laboratory assessments (hematology, chemistry, and uri-
nalysis). The individuals were excluded if they had within the
previous 30 d consumed drugs known to signiﬁcantly induce or
inhibit drug-metabolizing enzymes, or had taken within the 10
d prior to the ﬁrst administration of the investigational product any
prescription drugs or over-the-counter drugs. Written informed
consent was obtained from each of the participants prior to
screening, and a detailed explanation of the study was provided.2.2. Study design
This study was conducted in an open-label, 1-sequence, 2-
period crossover design at the Clinical Trial Center of Chonbuk
National University Hospital (Jeonju, Republic of Korea; Fig. 1). The
following ﬁve CYP substrate drugs were used to assess major drug
metabolizing enzyme-mediated drug interactions: caffeine
(200 mg, Vivarin, Meda Consumer Healthcare Inc., Marietta, GA,
USA) as a CYP1A2 substrate; losartan (50 mg, Cozaar, MSD Korea
Ltd., Seoul, Korea) as a CYP2C9 substrate; omeprazole (20 mg, Losec
capsule, AstraZeneca Korea, Seoul, Korea) as a CYP2C19 substrate;
dextromethorphan (15 mg, Robitussin Long-Acting CoughGels,
Pﬁzer Inc., New York, NY, USA) as a CYP2D6 substrate; and mid-
azolam (7.5 mg, Dormicum, Roche Korea, Seoul, Korea) as a CYP3A4
substrate. For assessment of drug transporter protein-mediated
drug interactions, fexofenadine (30 mg, Allegra, Handok Pharma-
ceutical Co., Ltd., Seoul, Korea) was administered as a P-gp
substrate.
During the pharmacokinetic phase, fasting individuals received
a “CYP probe drug cocktail” (caffeine 200 mg þ losartan 50
mgþ omeprazole 20 mgþ dextromethorphan 30 mgþmidazolam
7.5 mg along with 240 mL of water) on Days 1 and 15 at 8 AM. Blood
samples for pharmacokinetic analysis of the ﬁve CYP probe drugs
were collected before dosing (baseline) and at 0.25 h, 0.5 h, 1 h,
1.5 h, 2 h, 3 h, 4 h, 5 h, 6 h, 8 h, 10 h, 12 h, and 24 h after dosing. On
Days 2 and 16, each participant received a “P-gp probe drug”
(fexofenadine 30 mg along with 240 mL of water) at 8 AM. Toivities of major cytochrome P450 enzymes and P-gp in healthy Korean volunteers. P-gp,
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sampled before dosing (baseline) and at 0.5 h, 0.75 h, 1 h, 1.5 h, 2 h,
3 h, 4 h, 6 h, 8 h, 12 h, 24 h, and 48 h after administration. The blood
samples were immediately centrifuged at 3,200 rpm (1,800g) for
10 min at 4C, and the resulting plasma was stored at 70C until
analysis.
Over the subsequent 2 wk (Days 4e17), one pouch (10 mL as the
daily recommended dose) of concentrated RG solution (dried
ginseng 64%, Hongsamjung Everytime; Korea Ginseng Corp., Dae-
jeon, Korea) was administered once daily. The individuals were
hospitalized from the evening on the day before administration of
the study drugs (Day 1 and Day 14) to the mornings of Day 3 and
Day 17. The individuals were continuously monitored by in-
vestigators throughout the study period. Adverse events (AEs) were
identiﬁed by asking general health-related questions as well as self-
reporting by the participants during the study. Physical examina-
tions, routine laboratory assessments and vital sign measurements
were performed at predeﬁned regular intervals throughout the
study.2.3. Bioanalytical methods
The plasma concentrations of the parents andmetabolites of the
ﬁve CYP probe drugs (caffeine and paraxanthine, losartan and EXP-
3174, omeprazole and 5-hydroxyomeprazole, dextromethorphan
and dextrorphan, and midazolam and 1-hydroxymidazolam) and
the P-gp probe drug (fexofenadine) were determined using a vali-
dated liquid chromatography-tandem mass spectrometry method.
The ginsenoside content [Rb1, Rb2, Rc, Re, F2, Rg1, 20(S)-Rg3,
20(R)-Rg3, 20(S)-Rh1, 20(S)/20(R)-Rh2, 20(R)-Rh1/Rd/F1, com-
pound K, compound O, compound Y, Protopanaxadiol (S), Proto-
panaxadiol (R), and Protopanaxatriol (S)] of the concentrated RG
solution product was analyzed using a GX-281 HPLC System UV/VIS
(Gilson, Inc., Middleton, WI, USA; Table 1).2.4. Genotype analysis of CYP2C9, CYP2C19, and CYP2D6
CYP enzyme activity was measured with a PyroMark ID (Biotage
AB, Uppsala, Sweden). The CYP2C9*2, CYP2C9*3, CYP2C19*2, and
CYP2C19*3 enzymes were measured using a pyrosequencing
method, and the CYP2D6*5 enzyme was measured using a poly-
merase chain reaction (PCR) method.Table 1
Ginsenoside contents in Red Ginseng products
Contents Ginsenoside concentration
Amount (mg/10 mL) Composition of ginsenosides (%)
Rb1 29.02  0.05 28.94  0.25
Rb2 4.63  0.27 4.62  0.22
Rc 15.68  0.69 15.64  0.52
Re 8.58  0.01 8.55  0.10
F2 0.12  0.03 0.12  0.03
Rg1 4.59  0.02 4.58  0.07
20(S)-Rg3 2.95  0.15 2.94  0.12
20(R)-Rg3 11.5  0.72 11.46  0.06
20(S)-Rh1 15.04  0.56 15.00  0.40
20(S)/20(R)-Rh2 0.02  0.01 0.02  0.00
20(R)-Rh1/Rd/F1 0.65  0.04 0.65  0.03
Compound K 0.06  0.02 0.06  0.02
Compound O 0.07  0.01 0.07  0.01
Compound Y 5.97  1.32 5.96  1.38
Protopanaxadiol(S) 0.13  0.00 0.12  0.00
Protopanaxadiol(R) 0.19  0.02 0.19  0.02
Protopanaxatriol(S) 1.08  0.08 1.08  0.09
Values are presented as mean  standard deviations2.5. Pharmacokinetic and statistical analysis
Individual PK parameters were obtained by noncompartmental
methods using Phoenix WinNonlin 6.3 software (Pharsight Cor-
poration, Sunnyvale, CA, USA). The maximum plasma concentra-
tion (Cmax) and time to Cmax (tmax) were obtained directly from
plasma concentrationetime curves. The area under the curve of the
last sampling time (AUClast) was calculated using the linear trape-
zoidal rule. CYP1A2, 2C9, 2C19, 2D6, and 3A4 activities were eval-
uated by calculating the metabolic ratios of caffeine, losartan,
omeprazole, dextromethorphan, and midazolam, respectively; the
metabolic ratios were calculated by determining their corre-
sponding metabolite/parent AUC ratios (AUClast, metabolite/AUClast,
parent) in plasma.
Statistical analysis was performed using SAS (Version 9.3, SAS
Institute Inc., Cary, NC, USA). Descriptive statistics were used to
summarize the pharmacokinetic data, and ANOVA at a 5% signiﬁ-
cance level was used to compare the pharmacokinetic parameters.
The point estimates and 90% conﬁdence intervals (CIs) of the ratios
of the geometric means ratios (after RG intake/before RG intake) of
the log-transformed Cmax and AUClast were compared. Additionally,
because the number of participants was small, we performed the
Wilcoxon Signed-Rank test.
As this was a descriptive study to evaluate the drug interaction
potential of RG, no formal sample size estimation was performed
prospectively for pharmacokinetic evaluations. In retrospect, this
study was well powered (> 80% power) to rule out a 20% decrease
or 25% increase in AUC when comparing Day 15 and 16 pharma-
cokinetic parameters to baseline with 90% conﬁdence. Only the
AUC of dextromethorphan was not as well powered (59%) at the
sample level of conﬁdence.3. Results
A total of 15 healthy volunteers (with a mean  standard de-
viation age of 24.5  1.9 yr, a mean height of 173.9  5.7 cm, and a
mean weight of 68.9  9.1 kg) were determined to be eligible for
the study and enrolled. After a volunteer chose to withdraw, the
data for this individual were excluded from the study; the
remaining 14 individuals completed the study. CYP enzyme geno-
typing was assessed in 14 individuals, and none of the participants
were found to be genetically poor metabolizers of CYP2C9*2/*2, *2/
*3, or *3/*3, CYP2C19 *2/*2, *2/*3, or *3/*3, or CYP2D6 *5/*5
(Table 2).3.1. Effects of Red Ginseng on CYP enzymes
The pharmacokinetic parameters of the 14 participants
completing the study according to the protocol were evaluated. The
mean plasma concentrationetime proﬁles of the CYP and P-gp
probe drugs are shown in Fig. 2. The metabolic ratio between the
parents and metabolites of each CYP probe drug are described
Table 3.Table 2
Genotypes and allele frequencies of CYP2C9, CYP2C19, and CYP2D6
Genotype No. (frequency, %)
CYP2C9 *1/*1 13 (92.9)
*1/*3 1 (7.1)
CYP2C19 *1/*1 11 (78.6)
*1/*3 3 (21.4)
CYP2D6 *1/*1 14 (100)
Gene deletion 0 (0)
Fig. 2. Mean (standard deviation) plasma concentrationetime proﬁles of a cocktail of ﬁve probe drugs and their metabolites, as well as fexofenadine, before and after adminis-
tration of Red Ginseng. P-gp, P-glycoprotein; RG, Red Ginseng.
J Ginseng Res 2016;40:375e381378
Fig. 2. (continued).
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50,454.8 h*ng/mL, respectively, on Day 1 (before RG intake); these
values were 6,222.4 ng/mL and 55,992.3 h*ng/mL, respectively, on
Day 15 (after RG intake). The mean Cmax and AUClast of para-
xanthine, a metabolite of caffeine, were 1,461.2 ng/mL and
24,682.6 h*ng/mL, respectively, on Day 1 (before RG intake), and
these values were 1,444.3 ng/mL and 23,835.0 h*ng/mL, respec-
tively, on Day 15 (after RG intake). The point estimate and 90% CI of
the ratios of the geometric means (after RG intake/before RG
intake) of Cmax and AUClast of caffeine were 0.930 (0.842e1.026)
and 1.110 (1.028e1.198), respectively, and that of the caffeine
metabolic ratio (i.e., paraxanthine AUC/caffeine AUC) for the eval-
uation of CYP1A2 enzyme activity was 0.870 (0.805e0.940).
The mean Cmax and AUClast of losartan were 223.9 ng/mL and
610.3 h*ng/mL, respectively, on Day 1 (before RG intake), but these
values decreased to 175.0 ng/mL and 529.4 h*ng/mL, respectively,
on Day 15 (after RG intake). The mean Cmax and AUClast of EXP3174,
a metabolite of losartan, were 562.5 ng/mL and 3,804.3 h*ng/mL,Table 3
Effects of Red Ginseng on metabolic ratios of cytochrome P450 probe drugs
Enzyme Analyte ratio n After RG Before RG
CYP1A2 Paraxanthine: caffeine 14 0.426 0.489
CYP2C9 EXP3174: losartan 14 5.427 6.233
CYP2C19 5-Hydroxyomeprazole: omeprazole 14 0.220 0.214
CYP2D6 Dextrorphan: dextromethorphan 14 3.955 2.881
CYP3A4 1-Hydroxymidazolam: midazolam 14 0.485 0.589
1) Wilcoxon Signed-Rank test
Metabolic ratio ¼ AUClast of metabolite/AUClast of parent
AUClast, area under the plasma concentrationetime curve from time 0 to the last measure
Ginsengrespectively, on Day 1 (before RG intake) and 457.2 ng/mL and
2,872.8 h*ng/mL, respectively, on Day 15 (after RG intake). The
point estimate and 90% CI of the ratios of the geometric means
(after RG intake/before RG intake) of Cmax and AUClast of losartan
were 0.782 (0.689e0.886) and 0.867 (0.799e0.941), respectively;
that of the losartan metabolic ratio, i.e., EXP3174 AUC/losartan AUC,
for the evaluation of CYP2C9 enzyme activity was 0.871 (0.800e
0.947).
For omeprazole, the mean Cmax and AUClast were 721.784 ng/mL
and 1,577.179 h*ng/mL, respectively, on Day 1 (before RG intake),
and these values were 626.256 ng/mL and 1,449.431 h*ng/mL,
respectively, on Day 15 (after RG intake). Themean Cmax and AUClast
of 5-hydroxyomeprazole, a metabolite of omeprazole, were
123.689 ng/mL and 338.141 h*ng/mL, respectively, on Day 1 (before
RG intake) and 109.126 ng/mL and 319.016 h*ng/mL, respectively,
on Day 15 (after RG intake). The point estimate and 90% CI of the
ratios of the geometric means (after RG intake/before RG intake) of
Cmax and AUClast of omeprazolewere 0.868 (0.697e1.080) and 0.919Geometric mean ratio, after RG:before RG (90% CI) CVw (%) p1)
0.870 (0.805e0.940) 11.62 0.0012
0.871 (0.800e0.947) 12.61 0.0023
1.027 (0.938e1.123) 13.50 0.5416
1.373 (0.864e2.180) 78.23 0.6257
0.824 (0.658e1.032) 34.60 0.0785
d time; CI, conﬁdence interval; CVw, intra-individual coefﬁcient of variation; RG, Red
J Ginseng Res 2016;40:375e381380(0.814e1.037), respectively, and that of the omeprazole metabolic
ratio, i.e., 5-hydroxyomeprazole AUC/omeprazole AUC, for the
evaluation of CYP2C19 enzyme activity was 1.027 (0.938e1.123).
Themean Cmax and AUClast of dextromethorphanwere 3.623 ng/
mL and 18.962 h*ng/mL, respectively, on Day 1 (before RG intake);
these values on Day 15 (after RG intake) were 3.334 ng/mL and
17.351 h*ng/mL, respectively. The mean Cmax and AUClast of dex-
trorphan, a metabolite of dextromethorphan, were 12.679 ng/mL
and 54.630 h*ng/mL, respectively, on Day 1 (before RG intake) and
13.663 ng/mL and 68.626 h*ng/mL, respectively, on Day 15 (after RG
intake). The point estimate and 90% CI of the ratios of the geometric
means (after RG intake/before RG intake) of Cmax and AUClast of
dextromethorphan were 0.920 (0.791e1.070) and 0.915 (0.605e
1.383), respectively, and that of the dextromethorphan metabolic
ratio, i.e., dextrorphan AUC / dextromethorphan AUC, for the
evaluation of CYP2D6 enzyme activity was 1.373 (0.864e2.180).
With regard to midazolam, the mean Cmax and AUClast were
41.142 ng/mL and 92.276 h*ng/mL, respectively, on Day 1 (before RG
intake); these values were 38.961 ng/mL and 104.053 h*ng/mL,
respectively, on Day 15 (after RG intake). Themean Cmax and AUClast
of 1-hydroxymidazolam, a metabolite of midazolam, were
38.766 ng/mL and 54.344 h*ng/mL, respectively, on Day 1 (before
RG intake) and 30.405 ng/mL and 50.507 h*ng/mL, respectively, on
Day 15 (after RG intake). The point estimate and 90% CI of the ratios
of the geometric means (after RG intake/before RG intake) of Cmax
and AUClast of midazolam were 0.947 (0.756e1.186) and 1.128
(1.000e1.271), respectively, and that of the midazolam metabolic
ratio, i.e., 1-hydroxymidazolam AUC/midazolam AUC, for the eval-
uation of CYP3A4 enzyme activity was 0.824 (0.658e1.032).
3.2. Effects of Red Ginseng on P-glycoprotein
The mean Cmax and AUClast of fexofenadine were 86.283 ng/mL
and 528.949 h*ng/mL, respectively, between Days 2 and 3 (before
RG intake); between Days 16 and 17 (after RG intake), these values
were 76.787 ng/mL and 509.561 h*ng/mL. The point estimate and
90% CI of the ratios of the geometric means (after RG intake/before
RG intake) of Cmax and AUClast of fexofenadine were 0.890 (0.681e
1.162) and 0.963 (0.845e1.098), respectively.
3.3. Safety assessment
The safety and tolerability of RG or the probe drugs were eval-
uated in all 14 of the participants. There were 23 adverse events in
10 of the participants, including dizziness (13 events), euphoric
mood (6 events), somnolence (2 events), headache (1 event) and
nausea (1 event). It is already well known that symptoms such as
dizziness, euphoric mood, and somnolence can be generated by
midazolam. All adverse events were mild, and all of the test par-
ticipants who showed adverse sequelae recovered; serious adverse
events were not observed.
The severity of all AEs was either mild or moderate, and all were
resolved without medical intervention. There were no clinically
signiﬁcant ﬁndings upon physical examination, including changes
in vital signs or in clinical laboratory evaluations.
4. Discussion
In this study, we used a cocktail technique to examine whether
RG affects CYP enzymes and P-gp. This technique employed the
concurrent evaluation of many metabolic enzymes and a transport
protein to assess induction/suppression effects using probe drugs.
Each probe drug was pre-evaluated for speciﬁcity for each meta-
bolic enzyme or transport protein and to verify no interactions with
the other probes. Therefore, the study utilized a cocktail of drugsthat were proven to be sufﬁcient as indicators before proceeding.
The probe drugs were selected in accordance with existing studies,
such as a Pittsburgh cocktail study [11], a Cooperstown cocktail
study [12] and an Inje cocktail study [13]. Many natural materials
can affect efﬂux proteins such as P-gp [14], even though conven-
tional cocktail combinations do not include a drug that probes for
this protein. To assess CYP enzyme activity, the present approach
incorporated the cocktail combination of the Inje study, a previous
drug interaction study that used a cocktail technique to evaluate
general drug interactions by calculatingmetabolic ratios for a probe
and its metabolite in plasma at certain time points. In 2012, the
Guideline on the Investigation of Drug Interactions published by
the European Medicines Agency recommended evaluating the
clearance and effect of AUC because metabolite-to-parent drug
ratios do not provide a true quantiﬁcation of effects on enzyme
activity [15]. Therefore, our study calculated pharmacokinetic pa-
rameters through drug concentrationetime curves in plasma to
obtain a real quantitative value. In addition, the 2-wk-long
administration of the daily recommended dose of ginseng products
should be sufﬁcient to induce or inhibit CYP enzymes [16].
The CYP indicator drugs used in this study, including caffeine,
losartan, omeprazole, dextromethorphan, and midazolam, are each
metabolized in the body by speciﬁc CYP enzymes [17e21].
Based on the results, the activities of the CYP1A2, CYP2C9, and
CYP3A4 enzymes were inhibited by RG product intake, whereas
CYP2C19 and CYP2D6 were not affected [22,23]. A previous con-
ventional in vitro study obtained similar results, asserting that
ginsenosides Rb1, Rb2, Rc, Re, and Rg1 did not affect CYP enzyme
activity but that their metabolites ginsenoside Rh2, compound K,
PPD, and PPT did inhibit CYP1A2, CYP2C9, and CYP3A4, with no
effect on CYP2C19 and CYP2D6 [4,5,10,24]. However, in this study,
administration of the ginseng product at its recommended daily
allowance resulted in a small inhibition of CYP1A2, CYP2C9, and
CYP3A4 activities, such that even if the drug was administered in
combination with CYP substrates, the effect was unlikely to be
clinically meaningful.
P-gp is not affected by the major ginsenosides of fresh ginseng
Rb1, Rb2, and Re, but it is known to be inhibited by compound K,
Rh2, PPD, and PPT, which are metabolites of ginsenosides that are
produced by intestinal bacteria [7e9]. In this study, the AUClast of
fexofenadine, the P-gp probe drug, did not change after the
administration of RG. This result suggests that the contents of
compound K, Rh2, PPD and PPT, which inhibit P-gp, increase during
the manufacturing process of RG from fresh ginseng. Although
fexofenadine is widely used as a P-gp probe drug [25,26], the use of
this compound in this study was limited because fexofenadine is a
substrate of OATP1B1, OATP1B3 and MRP2 as well as P-gp [27]. The
reasons for several of the differences between the results of existing
studies and the present ﬁndings are expected to be differences
between fresh ginseng and RG products that arise during the pro-
cessing of ginseng aswell as the ethnicities of the study participants.
Because it was performed on healthy volunteers, this study was
able to accurately assess drug interaction potentials to minimize
confounding factors, such as comorbidities and concomitant
medications. However, due to variations in the composition of the
RG product as a result of the manufacturing process, it is difﬁcult to
expect the same results from all ginseng products. Moreover, unlike
medicines, RG products are typically consumed at more than their
recommended doses, and there is a need to evaluate the in-
teractions in the body resulting from high doses.
5. Conclusion
In summary, RG does not affect CYP2C19 and CYP2D6, although
it does inhibit CYP1A2, CYP2C9, and CYP3A4; however, these
D.-S. Kim et al / Effect of Red Ginseng on CYP and P-gp 381results are not clinically relevant because of their small signiﬁcance
in this study. Additionally, it was veriﬁed that RG does not affect P-
gp. Therefore, this product has no relevant potential to cause
metabolic and transport drug interactions.
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